DENTAL PRODUCTS ADVISORY PANEL CHAIR RESIGNS FOLLOWING RELEASE OF IG PROBE; NOV. 3-4 PANEL MEETING WILL REVISIT UNCLASSIFIED MUSCLE MONITORING DEVICES
This article was originally published in The Gray Sheet
Charles Bertolami, DDS, University of San Francisco voluntarily resigned as chairman of FDA's Dental Products Advisory Panel following an investigation by the HHS Office of the Inspector General, according to a letter from FDA Deputy Commissioner for External Affairs Sharon Smith Holston to Rep. Joe Barton (R-Tex.). Manufacturers' complaints regarding the panel chair's failure to abide by appropriate procedure at the Dental Panel's Oct. 13, 1994 meeting on muscle monitoring devices prompted the investigation.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.